Emergent BioSolutions (EBS) Tops Q4 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Emergent BioSolutions (EBS) Tops Q4 EPS by 23c

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021

February 24, 2022 4:05 PM EST

Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of $518M, in line with prior guidanceUpdates full year 2022 guidance; provides guidance on Q1 2022 total revenues

GAITHERSBURG, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the fourth quarter and year ended December 31, 2021.

"Emergents performance in 2021 is a testament to our strategic focus... More